You are here

Evusheld

AstraZeneca’s Evusheld fails to improve Covid outcomes in Phase III trial

Clinical Trials Arena

Tue, 02/20/24 - 11:01 am

clinical trials

FDA yanks EUA for AstraZeneca’s Evusheld as COVID variants continue to evolve

Medical Marketing and Media

Thu, 01/26/23 - 05:07 pm

Emergency Use Authorization

AstraZeneca's Evusheld loses potency against new omicron subvariant, FDA warns

Fierce Pharma

Wed, 10/5/22 - 10:37 am

AstraZeneca's Evusheld nabs its first global nod as a COVID treatment

Fierce Pharma

Wed, 08/31/22 - 10:34 pm

Study shows AstraZeneca's Covid-19 mAb Evusheld may not work against dominant Omicron strain

Endpoints

Thu, 07/21/22 - 10:39 am

Omicron variant

AstraZeneca trots out Evusheld data to expand the COVID preventive drug into the treatment arena

Fierce Pharma

Wed, 06/8/22 - 11:09 pm

US sees spike in Paxlovid usage as Merck's molnupiravir and AstraZeneca's Evusheld are slower off the shelf

Endpoints

Wed, 05/25/22 - 11:47 pm

AstraZeneca says no severe virus cases or deaths after taking antibody

Morningstar

Thu, 04/21/22 - 10:51 am

AstraZeneca antibody drug effective against BA.2, study finds

Beckers Hospital Review

Mon, 03/21/22 - 10:37 pm

Omicron variant